Psyence Biomedical Ltd.
PBM
$0.5168
-$0.0165-3.09%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.84% | 24.04% | -0.36% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.64% | -32.22% | -31.28% | -- | -- |
| Operating Income | 2.64% | 32.22% | 31.28% | -- | -- |
| Income Before Tax | -1,204.64% | -1,236.28% | -1,503.50% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,204.64% | -1,236.28% | -1,503.50% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,204.64% | -1,236.28% | -1,503.50% | -- | -- |
| EBIT | 2.64% | 32.22% | 31.28% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -574.06% | -610.35% | -1,454.11% | -- | -- |
| Normalized Basic EPS | 43.21% | 56.23% | 72.89% | -- | -- |
| EPS Diluted | -574.07% | -610.35% | -1,454.11% | -- | -- |
| Normalized Diluted EPS | 43.22% | 56.23% | 72.89% | -- | -- |
| Average Basic Shares Outstanding | 252.53% | 1,048.73% | 702.85% | -- | -- |
| Average Diluted Shares Outstanding | 177.17% | 474.36% | 802.85% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |